{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:22:55Z","timestamp":1763194975537,"version":"3.45.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06568-8","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T05:59:25Z","timestamp":1756533565000},"page":"5485-5491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic stem cell transplantation with prior pembrolizumab and bendamustine therapy induce complete metabolic response in relapsed\/refractory classical hodgkin lymphoma with relapse after nivolumab"],"prefix":"10.1007","volume":"104","author":[{"given":"Ugo","family":"Giordano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Ku\u015b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"K\u0119dziora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Podgajny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Mordak-Domaga\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Dybko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Dybko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"6568_CR1","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory hodgkin\u2019s lymphoma. J Clin Oncol 30:2183\u20132189","journal-title":"J Clin Oncol"},{"key":"6568_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended Follow-Up of the multicohort Single-Arm phase II checkmate 205 trial. J Clin Oncol 36:1428\u20131439","journal-title":"J Clin Oncol"},{"key":"6568_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ et al (2019) Pembrolizumab in relapsed or refractory hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134:1144\u20131153","journal-title":"Blood"},{"key":"6568_CR4","doi-asserted-by":"publisher","first-page":"1054314","DOI":"10.3389\/fonc.2022.1054314","volume":"12","author":"M Maranzano","year":"2022","unstructured":"Maranzano M, Mead M (2022) The role of transplantation in hodgkin lymphoma. Front Oncol 12:1054314","journal-title":"Front Oncol"},{"key":"6568_CR5","doi-asserted-by":"publisher","first-page":"102228","DOI":"10.1016\/j.trim.2025.102228","volume":"90","author":"A Salem","year":"2025","unstructured":"Salem A, Mehdizadeh M, Parkhideh S (2025) Allogenic stem cell transplantation response for relapsed or refractory hodgkin lymphoma patients: an experience in Iran. Transpl Immunol 90:102228","journal-title":"Transpl Immunol"},{"key":"6568_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/curroncol32020118","volume":"32","author":"S Ge","year":"2025","unstructured":"Ge S, Lepic K, Bhindi R et al (2025) Outcomes of allogeneic stem cell transplant in patients with relapsed\/refractory hodgkin lymphoma. Curr Oncol 32:118","journal-title":"Curr Oncol"},{"key":"6568_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12288-024-01800-3","volume":"41","author":"A Uysal","year":"2025","unstructured":"Uysal A, Soyer NA, Ozdogu H et al (2025) Long-term outcomes of allogeneic stem cell transplantation for relapsed\/refractory hodgkin and non-Hodgkin lymphoma: Multi-center experience from Turkey. Indian J Hematol Blood Transfus 41:43\u201352","journal-title":"Indian J Hematol Blood Transfus"},{"key":"6568_CR8","doi-asserted-by":"publisher","first-page":"8228","DOI":"10.1002\/cam4.5631","volume":"12","author":"MS Faisal","year":"2023","unstructured":"Faisal MS, Hanel W, Voorhees T et al (2023) Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory hodgkin lymphoma in the era of novel agents. Cancer Med 12:8228\u20138237","journal-title":"Cancer Med"},{"key":"6568_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/bjh.15685","volume":"184","author":"CK Brierley","year":"2019","unstructured":"Brierley CK, Jones FM, Hanlon K et al (2019) Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic Haematopoietic stem cell transplantation for patients with mature lymphoid malignancies. Br J Haematol 184:547\u2013557","journal-title":"Br J Haematol"},{"key":"6568_CR10","doi-asserted-by":"publisher","first-page":"634435","DOI":"10.3389\/fimmu.2021.634435","volume":"12","author":"N K\u00f6hler","year":"2021","unstructured":"K\u00f6hler N, Ruess DA, Kesselring R, Zeiser R (2021) The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation. Front Immunol 12:634435","journal-title":"Front Immunol"},{"key":"6568_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","volume":"4","author":"C De Philippis","year":"2020","unstructured":"De Philippis C, Legrand-Izadifar F, Bramanti S et al (2020) Checkpoint Inhibition before haploidentical transplantation with posttransplant cyclophosphamide in hodgkin lymphoma. Blood Adv 4:1242\u20131249","journal-title":"Blood Adv"},{"key":"6568_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales M-A et al (2013) Phase II study of Bendamustine in relapsed and refractory hodgkin lymphoma. J Clin Oncol 31:456\u2013460","journal-title":"J Clin Oncol"},{"key":"6568_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","volume":"25","author":"NA Carreau","year":"2020","unstructured":"Carreau NA, Pail O, Armand P et al (2020) Checkpoint Blockade treatment May sensitize hodgkin lymphoma to subsequent therapy. Oncologist 25:878\u2013885","journal-title":"Oncologist"},{"key":"6568_CR14","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1097\/HS9.0000000000000401","volume":"4","author":"KV Lepik","year":"2020","unstructured":"Lepik KV, Mikhailova NB, Kondakova EV et al (2020) A study of safety and efficacy of nivolumab and Bendamustine (NB) in patients with relapsed\/refractory hodgkin lymphoma after nivolumab monotherapy failure. HemaSphere 4:e401","journal-title":"HemaSphere"},{"key":"6568_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ajh.25154","volume":"93","author":"C Rossi","year":"2018","unstructured":"Rossi C, Gilhodes J, Maerevoet M et al (2018) Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from Lysa centers. Am J Hematol 93:1042\u20131049","journal-title":"Am J Hematol"},{"key":"6568_CR16","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW et al (2020) Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J Clin Oncol 38:3794\u20133804","journal-title":"J Clin Oncol"},{"key":"6568_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"6568_CR18","unstructured":"https:\/\/www.nccn.org\/guidelines\/guidelines-process\/about-nccn-clinical-practice-guidelines] . Accessed 19 Jun 2025"},{"key":"6568_CR19","doi-asserted-by":"crossref","unstructured":"Bickle I, Stasio M (2018) Lymphoma response to immunomodulatory therapy criteria (LYRIC). Radiopaedia.org","DOI":"10.53347\/rID-63718"},{"key":"6568_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl 22:4\u201310","journal-title":"Biol Blood Marrow Transpl"},{"key":"6568_CR21","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl 15:825\u2013828","journal-title":"Bone Marrow Transpl"},{"key":"6568_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl 21:389\u2013401e1","journal-title":"Biol Blood Marrow Transpl"},{"key":"6568_CR23","unstructured":"Auletta J, Chen M, Shaw BE (2021) Current use and outcome of hematopoietic stem cell transplantation. CIBMTR US summary slides"},{"key":"6568_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","volume":"55","author":"MM Rivas","year":"2020","unstructured":"Rivas MM, Berro M, Prates MV et al (2020) Allogeneic stem cell transplantation improves survival in relapsed hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transpl 55:117\u2013125","journal-title":"Bone Marrow Transpl"},{"key":"6568_CR25","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/cancers13071702","volume":"13","author":"J Stokes","year":"2021","unstructured":"Stokes J, Molina MS, Hoffman EA et al (2021) Immunomodulatory effects of Bendamustine in hematopoietic cell transplantation. Cancers (Basel) 13:1702","journal-title":"Cancers (Basel)"},{"key":"6568_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU et al (2019) Significant risk of Graft-versus-Host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transpl 25:94\u201399","journal-title":"Biol Blood Marrow Transpl"},{"key":"6568_CR27","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1038\/s41375-020-0851-8","volume":"34","author":"JC Nieto","year":"2020","unstructured":"Nieto JC, Rold\u00e1n E, Jim\u00e9nez I et al (2020) Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia 34:3420\u20133425","journal-title":"Leukemia"},{"key":"6568_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s12185-020-02960-4","volume":"112","author":"A Ito","year":"2020","unstructured":"Ito A, Kim S-W, Matsuoka K-I et al (2020) Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory hodgkin lymphoma: a multicenter retrospective study. Int J Hematol 112:674\u2013689","journal-title":"Int J Hematol"},{"key":"6568_CR29","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.3324\/haematol.2024.284968","volume":"109","author":"E Kaphan","year":"2024","unstructured":"Kaphan E, Bettega F, Vallet N et al (2024) PD-1 Blockade and allogeneic hematopoietic stem cell transplantation in hodgkin lymphoma, a matter of time: a National study on behalf of the Soci\u00e9t\u00e9 Francophone de greffe de Moelle et de th\u00e9rapie cellulaire. Haematologica 109:3373\u20133378","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06568-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06568-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06568-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:18:55Z","timestamp":1763194735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06568-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6568"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06568-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from the subject involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The consent to publish was obtained from the subject involved in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors declare no financial or non-financial competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}